본문으로 건너뛰기
← 뒤로

Pilli Kai Score: A Proposed Digital Twin Framework Integrating Radiomics and Biomarkers for Enhanced Lung Nodule Risk Stratification.

1/5 보강
Cureus 📖 저널 OA 99.9% 2021: 42/43 OA 2022: 79/79 OA 2023: 181/181 OA 2024: 284/284 OA 2025: 774/774 OA 2026: 506/506 OA 2021~2026 2026 Vol.18(2) p. e104310
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
환자: intermediate pre-test probability
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
No patient-level data are analyzed; instead, illustrative figures present the proposed workflow and anticipated performance benchmarks. If validated in multi-center studies, this framework could improve diagnostic accuracy, reduce avoidable interventions, and enable more personalized lung cancer care pathways.

Khalpey Z, Pilli S

📝 환자 설명용 한 줄

Indeterminate pulmonary nodules are a frequent and challenging finding in both screening and incidental imaging.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Khalpey Z, Pilli S (2026). Pilli Kai Score: A Proposed Digital Twin Framework Integrating Radiomics and Biomarkers for Enhanced Lung Nodule Risk Stratification.. Cureus, 18(2), e104310. https://doi.org/10.7759/cureus.104310
MLA Khalpey Z, et al.. "Pilli Kai Score: A Proposed Digital Twin Framework Integrating Radiomics and Biomarkers for Enhanced Lung Nodule Risk Stratification.." Cureus, vol. 18, no. 2, 2026, pp. e104310.
PMID 41909290 ↗

Abstract

Indeterminate pulmonary nodules are a frequent and challenging finding in both screening and incidental imaging. Existing clinical prediction models provide structured estimates of malignancy risk but remain limited in precision, particularly for patients with intermediate pre-test probability. This technical report proposes the Pilli Kai Score, a digital twin framework that integrates clinical variables, radiomic features, blood-based biomarkers, and positron emission tomography (PET) data into a unified probability estimate for malignancy. The framework outlines a multi-modal modeling strategy incorporating validated clinical predictors, standardized radiomics, biomarkers evaluated in pulmonary nodule populations, and PET categories when available. Prespecified validation targets include strong calibration across risk strata, an area under the receiver operating characteristic (ROC) curve exceeding 0.85, and a high negative predictive value to safely defer invasive procedures in benign disease, with comparative evaluation against established clinical models. No patient-level data are analyzed; instead, illustrative figures present the proposed workflow and anticipated performance benchmarks. If validated in multi-center studies, this framework could improve diagnostic accuracy, reduce avoidable interventions, and enable more personalized lung cancer care pathways.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기